Phase I/IIa Study for AZD5335 as monotherapy and in combination with anti-cancer agents in participants with Solid Tumors - FONTANA

Study identifier:D8990C00001

ClinicalTrials.gov identifier:NCT05797168

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination with Anti-cancer Agents in Participants with Solid Tumors.

Medical condition

ovarian cancer, Lung Adenocarcinoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD5335, AZD5305

Sex

All

Estimated Enrollment

150

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 05 Jun 2023
Estimated Primary Completion Date: 01 Nov 2027
Estimated Study Completion Date: 01 Nov 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria